

Probiome for Canine Bladder Cancer



The purpose of this study is to determine if the addition of a probiotic can improve clinical outcomes when paired with a standard-of-care therapy (vinblastine / piroxicam) for canine bladder cancer - also known as urothelial carcinoma or transitional cell carcinoma (TCC). We will evaluate tumor response, clinical side effects, and quality of life as part of this study. Additionally, we will evaluate immune response and characterize the stool and urine microbiome and metabolome to understand the potential effects of the probiotic. Our broader goal is to improve cancer care and outcomes in dogs with bladder cancer.

What qualifies my pet?

- Strongly suspected of having urothelial carcinoma by the referring veterinarian
- All cases will be biopsy confirmed at OSUCVM following initial screening
- Cancer must be primarily located within the bladder.
- Females weighing at least 6kg
- Males must weigh at least 10kg and be able to pass a catheter of minimum size through the urethra.
- Normal weight (BCS 4-7)
- Complete blood count and serum chemistry without clinically significant abnormalities, as determined by veterinarian.

Client compensation

Screening and 8 weeks of medical management for your dog's bladder cancer will be covered by the study. Study medication will be provided for the duration of the study. Limited funds are also available to cover certain adverse events secondary to the treatment protocol and in accordance with your veterinary team's recommendations. Owners will be financially responsible for all costs associated with bladder cancer management after the 8-week trial period, and for diagnostics and treatments associated with presumed tumor progression.

**Learn more
and pre-screen here:**

